NCT06160531View on ClinicalTrials.gov

Influenza Viral Challenge Study of CC-42344 in Healthy Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 25, 2023

Primary Completion Date

May 3, 2024

Study Completion Date

July 18, 2024

Conditions
Influenza A
Interventions
DRUG

CC-42344

Anti-influenza A agent

DRUG

Placebo

Matching placebo

Trial Locations (1)

E1 2AX

Queen Mary BioEnterprises Innovation Centre, London

Sponsors
All Listed Sponsors
collaborator

hVIVO Services Limited

INDUSTRY

lead

Cocrystal Pharma, Inc.

INDUSTRY

NCT06160531 - Influenza Viral Challenge Study of CC-42344 in Healthy Participants | Biotech Hunter | Biotech Hunter